Volume 4, Number 1—March 1998
Perspective
Risk for Transfusion-Transmitted Infectious Diseases in Central and South America
Table 4
Cost (US$) |
||||||||
---|---|---|---|---|---|---|---|---|
HIV |
HBVb |
HCV |
T. cruzi |
|||||
Country | Single test | Preventing one infected unit | Single test | Preventing one infected unit | Single test | Preventing one infected unit | Single test | Preventing one infected unit |
Chile | 2.3 | 676 | 1.2c | 599 | 3.5d | 547 | NAe | NA |
Costa Rica | 1.1 | 3,280 | 0.5c | 111 | NA | NA | NA | NA |
Ecuadorf | 1.7 | 1,708 | 1.0c | 263 | 10.0 | 7,136 | 0.35g | 175 |
El Salvador | 2.0 | 1,550 | 1.9c | 238 | 4.5 | 1,802 | 1.0g,h 1.0 | 68 |
Guatemala | 1.8 | 601 | 1.7c | 243 | 3.5 | 438 | 0.9g | 65 |
Honduras | 0.9 | 232 | 0.9c 0.5h | 334 186 | 3.5 | 6,971 | 0.45h | 36 |
Nicaragua | 1.0 | 23,000 | 0.5h | 125 | 3.5 | 797 | 0.5h | 209 |
Peru (Lima) | 2.4 | 858 | 3.5c 2.4i | 407 279 | 8.2 | 1,862 | 0.25g | 11 |
Venezuela | 1.3 | 619 | 1.3c | 90 | 4.5 | 479 | 0.5 0.3g | 38 23 |
aCost of preventing (=detecting) one infected unit was calculated as [(number of donors x test cost) ÷ (total number of positive donors detected)]. All costs refer to enzyme-linked immunosorbent assay, unless otherwise indicated.
bHBsAg only
cEnzyme immunoassay.
dEstimated cost based on cost of test in other countries.
eData not available.
fDonors and prevalence for 1994, costs for 1993.
gIndirect hemagglutination.
hRadioimmunoassay.
iPassive reverse hemagglutination.
Page created: December 16, 2010
Page updated: December 16, 2010
Page reviewed: December 16, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.